 Home > Active Ingredient News > Drugs Articles > China author The first study on the current status of cancer incidence and access to health services in children and adolescents in China

China author The first study on the current status of cancer incidence and access to health services in children and adolescents in China

 Last Update: 2022-10-01
 Source: Internet
 Author: User

Tags

5 4 simplified

paper cross

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The Lancet publishes a nationwide cross-sectional study of cancer incidence and access to health services in children and adolescents completed by the team of Professor Ni Xin of Beijing Children's Hospital, Capital Medical University, National Center for Children's Medicine
。 The results show that from 2018 to 2020, a total of 121,145 children and adolescents in China were diagnosed with cancer, with an average incidence rate of 126.

Research background

Cancer is one of the leading causes of death among children and adolescents worldwide [1,2].

The low incidence of reported LMICs may be associated with inadequate reporting systems or insufficient diagnostic capacity due to weak health systems [7].

On June 12, 2019, the National Center for Pediatric Cancer Surveillance (NCPCS) was approved by the National Center for Pediatric Cancer Surveillance, NCPCS, which establishes a hospital-based national paediatric cancer surveillance system covering 31 provinces, municipalities and autonomous regions except Hong Kong, Macao and Taiwan, aiming to continuously collect information on childhood cancer patients in China and provide comprehensive, scientific, and scientific information for the national prevention and control of childhood tumors.

Purpose of the study

For the first time at the national and regional levels, the study systematically reports on the incidence of cancer in children and adolescents of different genders and age groups based on the third revision of International Classification of Childhood Cancer (ICCC-3) in China, as well as the distribution of health service resources related to diagnosis.

Research Methods

In this nationwide cross-sectional study, we used databases such as NCPCS, hospital quality monitoring systems, and others to estimate the incidence of cancer in children (aged 0-14 years) and adolescents (aged 15-19 years) in China from January 1, 2018 to December 31
, 2020, using a hierarchical proportional algorithm.

Results of the study

Figure 1.

Figure 2.

Figure 3.

4.
Cross-regional medical treatment of new cancer patients in children and adolescents in China

Among the new cases of cancer in children and adolescents, the proportion of patients who sought medical treatment across regions was 22.
16%.

Among different cancer groups, retinoblastoma had the highest proportion of cross-regional medical treatment, reaching 56.
54%; Among different regions, the proportion of inter-regional medical treatment in low HDI areas was the highest, at 35.
14%; At the same time, with the increase of HDI levels, the proportion of new patients seeking medical treatment across regions gradually decreased (Figure 4
).

Figure 4.
Proportion of new cancer patients in children and adolescents across regions and 11 major diagnostic groups in different HDI regions (%)

conclusion

This study is the first to use the nationally representative data of NCPCS and hospital quality monitoring system to systematically and comprehensively report the latest incidence of cancer in children and adolescents in China based on the ICCC-3 disease classification system, and for the first time to reveal the differences in cancer incidence and access to health services in different levels of economic development and the relationship between
the two 。 The results of this study provide strong data support for accurately assessing the burden of cancer disease in children and adolescents in China; At the same time, it was found that access to health services, as one of the determinants of health society, plays an important role
in the incidence of cancer in children and adolescents in China.
In achieving the goals of the United Nations Sustainable Development Goals and the Healthy China 2030 Framework, policymakers should prioritize access to health services for early diagnosis of childhood cancer to improve disease outcomes, reduce the burden of disease, and reduce regional disparities
in the ability to diagnose and treat cancer in children and adolescents.

Related comments

Professor Sumit Gupta from The Hospital for Sick Children, Canada, Canada, who was not involved in the study, noted in his comments that the study not only quantified the incidence of cancer in children and adolescents and the accessibility of health services for cancer diagnosis, but also proposed interventions to further improve the status of childhood cancer in China.
This is commendable and gives people considerable optimism about the medical development of childhood tumors
.
Professor Sumit Gupta highly praised the study, which represents a highly successful childhood cancer initiative of LMICs, in response to the World Health Organization's Global Initiative on Childhood Cancer, contributing to significant advances in global childhood cancer control
.
At the same time, he called on "the international community to seize the opportunity to learn from each other, work together and work together for the future, so that every child's healing opportunities are no longer limited by geography"
.

Team introduction

This study was completed by the pediatric oncology research team of Professor Ni Xin of Beijing Children's Hospital affiliated to Beijing Children's Medical University of the National Center for Children's Medicine, whose founders were Academician Zhang Jinzhe and Academician Hu Yamei of the Chinese Academy of
Engineering.
Other participants in the study were from the Cancer Hospital
of the Chinese Academy of Medical Sciences.

References

1.
Murphy SL, Xu J, Kochanek KD.
Deaths: final data for 2010.
Natl Vital Stat Rep 2013; 61: 1–117.

2.
Howlader N, Noone AM, Krapcho M, et al.
SEER Cancer Statistics Review, 1975–2018, April 15, 2021.

https://seer.
cancer.
gov/csr/1975_2018/ (accessed Dec 13, 2021).

3.
Magrath I, Steliarova-Foucher E, Epelman S, et al.
Paediatric cancer in low-income and middle-income countries.
Lancet Oncol 2013; 14: e104–16.

4.
Lam CG, Howard SC, Bouffet E, Pritchard-Jones K.
Science and health for all children with cancer.
Science 2019; 363: 1182–86.

5.
Zheng R, Peng X, Zeng H, et al.
Incidence, mortality and survival of childhood cancer in China during 2000–2010 period: a population-based study.
Cancer Lett 2015; 363: 176–80.

6.
Sun K, Zheng R, Zhang S, et al.
Patterns and trends of cancer incidence in children and adolescents in China, 2011–2015: a population-based cancer registry study.
Cancer Med 2021; 10: 4575–86.

7.
Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Atun R.
Estimating the total incidence of global childhood cancer: a simulation-based analysis.
Lancet Oncol 2019; 20: 483–93.

8.
Song P, Ren Z, Chang X, Liu X, An L.
Inequality of paediatric workforce distribution in China.
Int J Environ Res Public Health 2016; 13: E703.

9.
Anand S, Fan VY, Zhang J, et al.
China’s human resources for health: quantity, quality, and distribution.
Lancet 2008; 372: 1774–81.

10.
Gatta G, Botta L, Rossi S, et al.
Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5–a population-based study.
Lancet Oncol 2014; 15: 35–47.

11.
Sullivan R, Kowalczyk JR, Agarwal B, et al.
New policies to address the global burden of childhood cancers.
Lancet Oncol 2013; 14: e125–35.

12.
Pritchard-Jones K, Pieters R, Reaman GH, et al.
Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries.
Lancet Oncol 2013; 14: e95–103.

13.
Ribeiro RC, Steliarova-Foucher E, Magrath I, et al.
Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study.
Lancet Oncol 2008; 9: 721–29.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.